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Abstract
Background: Opioids are good painkillers, but many patients treated with opioids as painkillers developed a
secondary addiction. These patients need to stop misusing opioids, but the mild-to-severe clinical symptoms
associated with opioid withdrawal risk increasing their existing pain. In such cases, ketamine, which is used by
anaesthetists and pain physicians to reduce opioid medication, may be an effective agent for managing opioid
withdrawal.
Case presentation: We describe the case of a woman who developed a severe secondary addiction to opioids in
the context of lombo-sciatic pain. She presented a severe opioid addiction, and her physicians refused to prescribe
such high doses of opioid treatment (oxycontin® extended-release 120 mg daily, oxycodone 60 mg daily, and
acetaminophen/codeine 300 mg/25 mg 6 times per day). To assist her with her opioid withdrawal which risked
increasing her existing pain, she received 1 mg/kg ketamine oral solution, and two days after ketamine initiation
her opioid treatment was gradually reduced. The patient dramatically reduced the dosage of opioid painkillers and
ketamine was withdrawn without any withdrawal symptoms.
Conclusion: Ketamine displays many interesting qualities for dealing with all symptoms relating to opioid withdrawal.
Accordingly, it could be used instead of many psychotropic treatments, which interact with each other, to help with
opioid withdrawal. However, the literature describes addiction to ketamine. All in all, although potentially addictive,
ketamine could be a good candidate for the pharmacological management of opioid withdrawal.
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Background
Opioid addiction affects 15.5 million people in the
world, including 11.1 million heroin users (WHO)
(United Nations Office on Drugs and Crime, 2007) [1].
Although in the USA, opioid prescriptions rose between
2002 and 2010 but have been decreasing since 2013,
owing to physicians’ awareness of a rise in the opioid-
related death rate and the increase in opioid medications
[2]. Consequently, these patients need to end their
misuse of opioids, but the mild to severe clinical
symptoms associated with opioid withdrawal risk in-
creasing the pain already present. Such symptoms are
dysphoria, restlessness, rhinorrhea, lacrimation, myal-
gias, arthralgias, nausea, vomiting, abdominal cramps,
diarrhea, yawning, increased flatulence and piloerection.
Accordingly, in cases of severe somatic or psychiatric
withdrawal symptoms, it might be preferable to manage
opioid withdrawal when patients are hospitalized
(Guidelines for the management of opioid withdrawal,
WHO, 2009) [3]. There is a risk of complications such
as distress, increased heart rate, high or low blood pres-
sure. Anxiety, depression and, more rarely, psychotic ep-
isodes have been described when opioids are stopped
suddenly [4–6]. Opiate withdrawal may be done grad-
ually, using opiate substitution drugs such as methadone
or buprenorphine, or abruptly. In the latter case, with-
drawal symptoms are managed with adjunctive
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medication such as clonidine and benzodiazepine, and
medication to treat the symptoms. Clonidine binds to a
central alpha 2 adrenergic receptor that shares potassium
channels with opioids and blunts withdrawal symptoms.
In addition to clonidine, benzodiazepines and other
GABAergic drugs reduce catecholamine release during
severe withdrawal, and the benzodiazepines themselves
have been shown to reduce withdrawal symptoms in
animal models [7, 8]. Symptomatic medications such as
loperamide, phosphoglucinol, and octreotide could be
added for gastro-intestinal symptoms. Thus, managing
opiate withdrawal requires multiple prescriptions, with a
high risk of drug-drug interaction and incomplete patient
relief, a particularly sensitive issue in the case of patients
taking opioid drugs in the context of pain associated with
somatic disease.
In such cases, it might be worth investigating whether
ketamine, widely used by anaesthetists to limit opioid
tolerance, reduce use of painkillers, and increase the
time preceding the first request for painkillers during
the postoperative period [9], may be efficient for man-
aging opioid withdrawal. Ketamine has also shown it has
a role to play as an anti-hyperalgesic and tolerance-
protective drug. It is acknowledged that it is of interest
for managing various pain conditions, such as pain con-
nected with opioid tolerance, acute pain or chronic pain
[10–12]. Pain physicians use ketamine at sub-anaesthetic
doses to treat refractory chronic pain syndromes, espe-
cially cancer- and non-cancer-related pain, or pain with
a neuropathic component [13–15]. Moreover, recent
publications showed that use of alpha2-adrenoreceptor
agonists such as clonidine and NMDA antagonists such
as ketamine or dextromethorphan could minimize toler-
ance development during opioid treatment [16]. As well
as the tolerance effect, it is well known that chronic
opioid medication can potentially increase subjective
pain when prescribed for a long period [17]. Chronic
treatment with opioids may also be complicated by
abnormal pain sensitivity such as opioid-induced hyper-
algesia [18, 19]. In cancer pain patients who have lost
an analgesic response to high doses of opioids, a syn-
ergistic effect between oral ketamine and opioids and
a rightward shift of the opioid-response curve were
observed [20].
Ketamine is classified as an NMDA receptor antagon-
ist but has many other pharmacological actions on mu,
delta, kappa opioid receptors and monoamine trans-
porters, inhibiting serotonin, dopamine and norepineph-
rine reuptake. Low doses of ketamine reduce morphine
use, nausea and vomiting after surgery [21, 22], an effect
mediated by NMDA antagonism plus μ-opioid and
sigma receptor activation. In the central nervous system,
ketamine, like other NMDA receptor antagonists, trig-
gers anesthetic, amnesic, dissociative, and hallucinogenic
effects. Activation of κ-opioid receptors and possibly
sigma and mACh receptors may also contribute to its
psychotomimetic properties [21]. Dopamine and sero-
tonin reuptake inhibition is likely to underlie an anti-
depressant effect which is clinically relevant in depressed
patients [23], although an additional but weak action of
μ-opioid receptor activation cannot be ruled out [21]. In
peripheral systems, ketamine enhances catecholaminer-
gic transmission, producing measurable changes in per-
ipheral organ systems, including the cardiovascular,
gastrointestinal, and respiratory systems [24], increasing
sympathetic stimulation of the cardiovascular system,
and reducing nausea and vomiting and respiratory com-
plications like bronchoconstriction. However, ketamine
side effects may induce aberrant percepts, including
musical and auditory verbal hallucinations [25], and its
repetitive administration may lead to the development of
additive behavior [26, 27]. Accordingly, its use in
medical care should be strictly supervised.
Some studies looked at the effect of ketamine for man-
aging opioid withdrawal in the case of precipitated
opiate withdrawal. One study, involving 58 patients who
underwent rapid opiate antagonist induction under gen-
eral anesthesia, showed that ketamine could help man-
age opioid withdrawal [28]. Prior to opiate antagonist
induction, patients were given either a placebo (nor-
mal saline) or subanaesthetic ketamine infusion of
0.5 mg/kg/h. The ketamine group presented better control
of withdrawal symptoms, lasting beyond the ketamine in-
fusion itself. Significant differences were noted between
the ketamine and control groups in the anaesthetic and
early postanaesthetic phases, but no differences in effects
were observed in terms of outcome after 4 months. In the
same year, a Japanese team reported the case of a 2 year-
old girl who received ketamine perfusion to manage
symptoms caused by opioid withdrawal precipitated by
naloxone [29]. To the best of our knowledge, there is no
literature on ketamine use in opioid withdrawal not pre-
cipitated by naloxone. Here we report, according to the
CARE (CAse REport) guidelines [30], the case of a
36 year-old woman hospitalized for opioid painkiller
addiction who was treated with ketamine for the purpose
of opioid reduction and withdrawal.
Case presentation
In 2015, a 36 year-old woman was admitted to the
rheumatology department of Strasbourg University Hos-
pital (CHU) suffering from lumbar pain (or low back
pain) with hyperalgesia and addiction to painkillers. A
divorced mother of a child, the patient had been
employed until 2008. Her medical history included
chronic spinal pain over a one-year period, two cases of
deep vein thrombophlebitis (2001), pulmonary embolism
(2001), a transient ischaemic attack (2004) with negative
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blood test results, and an appendectomy (2008). Owing
to the functional consequences of left wrist surgery
following a work accident, she left her job and received
disability benefits. In 2014, she received opioid treatment
and 3 epidural infiltrations for lumbar and radicular
pain. As an outpatient, she was treated with pregabalin
combined with transcutaneous electrical nerve stimula-
tion (TENS), but the hospital then lost track of her. Her
psychiatric and addictological record contained reports
of an episode of depression, a morphine overdose-
induced coma, hospitalization for opioid withdrawal,
and an addiction to tobacco. When admitted to the
rheumatology department in 2015, her treatment
consisted of diazepam 10 mg three times per day, hy-
droxyzine 100 mg twice daily, venlafaxine 150 mg in the
morning, oxycontin® extended-release 60 mg twice daily,
oxycodone 10 mg every 4 h, and acetaminophen/codeine
300 mg/25 mg 6 times per day. She abused oxycodone
and codeine, and her physicians refused to prescribe opi-
oid treatment in such high dosages. Her medical exam-
ination revealed lumbosacral pain with intermittent
irradiation towards the posterior side of her thigh down
to the top of her left knee, painful limitation of flexion,
extension, right rotation of the spine, limited flexion in
both directions. The patient also reported pain upon pal-
pation of the left pelvic-trochanter region, and cellulalgia
in the dorso-lumbar region. She was suffering from dys-
uria and constipation due to opioid treatment. Biological
investigations, CT-scan and X-ray results were normal.
A spinal MRI scan found lumbar degenerative disc
disease (L4-L5 and L5-S1). Rheumatologists asked for a
specialist opinion from a pain specialist, who, in view of
the patient’s prior psychiatric history, decided to contact
psychiatrists and addictologists for their opinion. The
patient presented with a histrionic personality (eg. need
to be the center of attention, dramatization within the
therapeutic relationship, reactivity of mood, excessive
sensitivity to criticism or disapproval, inappropriate se-
ductive appearance, rapidly shifting emotional states that
may appear superficial and rash decision-making accord-
ing to DSM-5 [31]). She also presented with some bor-
derline traits (eg. unstable interpersonal relationships
alternating idealization/devaluation, identity disturbance
with unstable sense of self, difficulty controlling anger,
transient paranoid ideations). Given the patient’s psychi-
atric symptoms and the fact that she wanted to withdraw
opioid treatment by herself and attempted to do so, the
physicians proposed she be admitted to the hospital’s
psychiatry department to be treated for opioid with-
drawal with the administration of ketamine to manage
lombo-sciatic pain. She was informed of the side effects
of ketamine and of the need to follow the protocol cor-
rectly and to report any opioid withdrawal symptoms.
Faced with the fact that no physician could prescribe
such high dosages of opioid medication, the patient
agreed to be transferred to the psychiatric department.
There she received ketamine oral solution (5 mg/ml,
magistral formulae) 1 mg/kg, and two days after keta-
mine initiation her opioid treatment was gradually re-
duced (10 % reduction in the initial dosage each two
days). The patient reported no withdrawal symptoms
(Clinical Opioid Withdrawal Symptoms score of 0/11 in
the first and seconds week after the physician started re-
ducing her opioid medication), pain or cravings while
her opioid treatment was being reduced. She complained
of no side effects of ketamine other than an unusual
weakness. However, because of her borderline and histri-
onic traits, the reduction in opioid treatment took lon-
ger, and we had to extend the period of ketamine
treatment. In fact, the patient’s need to be at the center
of attention caused many problems with other patients
and with nurses, who found her demands difficult to
deal with. As she presented with emotional and paranoid
reactions, the medical staff proposed a long weekend
break, thus interrupting her care and delaying her treat-
ment. Although we had to extend the hospitalization
period and ketamine treatment, in the end ketamine
withdrawal was achieved without withdrawal symptoms,
and the patient was discharged from the hospital. She
consulted her addictologist and psychiatrist. She now
takes very small dosage of opioids for pain relief (codeine
50 mg three times per day). To control administration
of the remaining opioid medication, it is administered
at home by a nurse. Functional re-education was also
organized.
Discussion
In this case, we reported on withdrawal of opioid medi-
cation in a woman presenting opioid addictive disorders
but also suffering from chronic lumbar pain that justified
the use of painkillers. According to DSM-5 criteria [31],
her opioid use disorder was severe, insofar as she could
not stop using opioids and, although she tried to lower
the dosage of opioid medication, she increased it each
time she got out of the hospital. Moreover, she risked
her life by overdosing on opioid medication. The deci-
sion to stop taking opioid painkillers was not a spontan-
eous request on the part of the patient but a decision
she took when she realized that no physician would pre-
scribe her such a high daily dose. In the literature, it has
been shown that replacing opioid medication with a sub-
stitution treatment of buprenorphine and buprenorphine-
naloxone is effective for chronic pain and offers patients a
good degree of satisfaction [32, 33]. However, as bupre-
norphine is off-label and buprenorphine-naloxone was
off-label in France at this time, these treatments should be
proposed only after withdrawal has been shown to have
failed. Accordingly, the patient had difficulty accepting the
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idea of withdrawing opioid medications but agreed to
reduce the dosage and to combine it with treatment, such
as ketamine, for her lumbar pain. Ketamine introduction
was easy, and the treatment was well tolerated by the
patient, apart from an unusual weakness. Under ketamine,
there were no opioid withdrawal symptoms (no nausea,
vomiting, abdominal cramps, diarrhea, yawning, piloerec-
tion, restlessness) during the 3 weeks of ketamine medica-
tion and reduced opioid dosage. This observation is
consistent with those described in the literature and con-
firms that ketamine could help cope with symptoms of
opioid withdrawal [34]. As the patient had a history of de-
pressive disorders, and as she was treated with antidepres-
sants (venlafaxine 150 mg daily), she was assessed daily
for depressive disorders by a physician. She showed no in-
crease in depressive symptoms. As suggested in our intro-
duction, the action of the ketamine on the dopamine and
serotonin neurotransmissions have an antidepressant ef-
fect [23], which has been very interesting in the present
case for avoiding depressive disorders which might
emerge in the event of opioid withdrawal. This antidepres-
sant effect was also interesting for avoiding a relapse in
the patient’s opiate addiction, which most of the time is
due to depressive behaviors induced by opioid decrease or
withdrawal.
In our present case report, we showed that it is pos-
sible to use ketamine to reduce and almost withdraw
opioid medications in the case of painful situations. We
did not precipitate opioid withdrawal with naloxone
before ketamine initiation, but, for the first time, keta-
mine was initiated just before opioid reduction. In this
way, the combination of ketamine and opioid treatments
reduced lumbosacral pain, and the use of ketamine
counteracted withdrawal signs due to opioid reduction.
Furthermore, we showed that ketamine could help
patients lower their consumption of opioid medication
with good tolerance levels, even if they present addictive
disorders. It could be another way of dealing with opioid
withdrawal symptoms in patients suffering from opioid
addictive behaviors which are often an obstacle for them.
Moreover, opioid withdrawal symptoms are currently
managed with polytherapy based on benzodiazepine, hy-
droxyzine, antipsychotics, clonidine and many symptom-
atic treatments for nausea, vomiting, diarrhea, etc. There
is uncertainty surrounding these associations, which are
sometimes also insufficient for dealing with dysphoric
symptoms, which are a main cause of relapse [5]. That is
why ketamine’s long-lasting antidepressant effects could
be very helpful during opioid withdrawal [23]. However,
our case report is very complex given that the patient was
prescribed many psychotropic and antidepressant medica-
tions, and it is difficult to conclude whether ketamine
alone could counter all physical and psychological with-
drawal symptoms in this case. Moreover, the patient’s
histrionic personality might affect the successful use of
ketamine due to her suggestibility. Since she received spe-
cial treatment in a psychiatric unit, she was the center of
attention during her spell in hospital. This attention prob-
ably made her feel she was a very special patient. This
situation led to a brief interruption in her hospitalization
and prolonged the ketamine treatment and care, such that
she did not have to confront her own issues. To assess
whether it is worth using ketamine to withdraw opioid
medication, it may be necessary to study this effect in a
clinical trial.
Conclusion
All in all, ketamine displays many interesting qualities for
dealing with all physical and psychological symptoms re-
lating to opioid withdrawal. Accordingly, we propose that
ketamine could be used instead of many psychotropic
treatments for helping with opioid withdrawal, and, in this
way, might be safer for patients suffering from addictive
behaviors. However, the literature also describes addiction
to ketamine [26, 27], which is why its use in patients suf-
fering from addictive behaviors must be subject to stron-
ger and stricter criteria. With this risk in mind, we
propose testing ketamine medication for dealing with opi-
oid withdrawal in the case of opioid addictive disorders in
a “proof of concept” open study.
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